Abbott Laboratories (NYSE:ABT) received an upgrade from Jefferies, which raised its rating to Buy from Hold, stating that the ...

Abbott Laboratories' second-largest division, diagnostics, continues to be a hindrance, while the FY group operating margin ...

Abbott Laboratories’ Debt totaled $15 Bil at the end of the latest quarter, while its market capitalization stands at $233 ...

ABT beats on Q2 earnings and revenues with double-digit growth in Medical Devices, yet shares fall 5% pre-market.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Abbott Laboratories stock tumbled Thursday after the maker of medical devices and nutrition products narrowed its full-year ...

Barclays analyst Matt Miksic maintained an Overweight rating and increased the price target from $158 to $159 on April 17, ...

Investing.com -- Jefferies upgraded Abbott Laboratories (NYSE: ABT) to Buy from Hold, calling the market reaction to the ...

If you wonder whether Abbott Laboratories (NYSE: ABT) is a good buy in Q2 2025, the answer is yes. The company’s management, portfolio, cash flow, capital return, and pipeline are why. The stock ...

Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...

Abbott Laboratories has a lower P/E than the aggregate P/E of 53.67 of the Health Care Equipment & Supplies industry. Ideally ...

"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly ...